Cover Image
Read Now

BRAF targeted therapy for patients with melanoma and active brain metastases a review of clinical effectiveness

Skin cancer is the most common cancer in Canada, with about 6,500 new cases of skin malignant melanoma reported in 2014, and 1250 Canadians expected to die from it in 2017. Approximately 40-60% of melanomas contain a mutation in the gene that encodes BRAF, which leads to constitutive activation of d...

Full description

Bibliographic Details
Main Authors: Ho, Chuong, Adcock, Lorna (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, October 18, 2017
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Melanoma / Secondary
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Canada
Melanoma / Drug Therapy
Treatment Outcome
Proto-oncogene Proteins B-raf / Antagonists & Inhibitors
Protein Kinase Inhibitors
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 02082nam a2200349 u 4500
001 EB001865446
003 EBX01000000000000001029526
005 00000000000000.0
007 tu|||||||||||||||||||||
008 190504 r ||| eng
100 1 |a Ho, Chuong 
245 0 0 |a BRAF targeted therapy for patients with melanoma and active brain metastases  |h Elektronische Ressource  |b a review of clinical effectiveness  |c Chuong Ho, Lorna Adcock 
250 |a Version 1.0 
260 |a Ottawa (ON)  |b Canadian Agency for Drugs and Technologies in Health  |c 2017, October 18, 2017 
300 |a 1 PDF file (16 pages)  |b illustrations 
505 0 |a Includes bibliographical references 
653 |a Melanoma / secondary 
653 |a Antineoplastic Agents 
653 |a Antineoplastic Combined Chemotherapy Protocols 
653 |a Canada 
653 |a Melanoma / drug therapy 
653 |a Treatment Outcome 
653 |a Proto-Oncogene Proteins B-raf / antagonists & inhibitors 
653 |a Protein Kinase Inhibitors 
700 1 |a Adcock, Lorna  |e [author] 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a CADTH rapid response report: summary with critical appraisal 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK513219  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a Skin cancer is the most common cancer in Canada, with about 6,500 new cases of skin malignant melanoma reported in 2014, and 1250 Canadians expected to die from it in 2017. Approximately 40-60% of melanomas contain a mutation in the gene that encodes BRAF, which leads to constitutive activation of downstream signaling in the MAP (mitogen-activated protein) kinase pathway. This Rapid Response report aims to review the clinical effectiveness and safety of dabrafenib plus trametinib and cobimetinib plus vemurafenib for patients with BRAF (human gene that encodes a protein called B-Raf) mutation positive metastatic melanoma with active brain metastasis 

Similar Items